Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

Indiana University300 enrolled

Overview

This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Type 1 Diabetes

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults ≥18 years of age * Clinical diagnosis of T1D * GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week * Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study * Willing and able to provide informed consent Exclusion Criteria: * No exclusion criteria other than those not meeting inclusion criteria above

Locations (7)

Hoag Memorial Hospital

Newport Beach, California, United States

RECRUITING

Emory University

Atlanta, Georgia, United States

RECRUITING

Northwestern University

Chicago, Illinois, United States

Outcomes

Primary Outcomes

Change in HbA1c by type of therapy

Change in HbA1c from baseline to over 1 year by those receiving GLP-1RA and SGLTi

Time frame: 1 year

Central Contacts

Kanchan Bhasin, MBBS

CONTACT

(317)-278-2752 kanbhas@iu.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.